Unoprostone - R-Tech Ueno Ltd
Alternative Names: Isopropyl unoprostone; Ocuseva; Rescula; UF-021; Unoprostone isopropyl 0.12%Latest Information Update: 05 Nov 2023
At a glance
- Originator R-Tech Ueno Ltd
- Developer R-Tech Ueno Ltd; Santen Pharmaceutical; Sucampo Pharmaceuticals
- Class Antiglaucomas; Antihypertensives; Eye disorder therapies; Prostaglandins; Small molecules; Vasodilators
- Mechanism of Action Nitric oxide stimulants; Potassium channel agonists; Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Glaucoma; Ocular hypertension
- Phase III Retinitis pigmentosa
- No development reported Age-related macular degeneration
- Discontinued Retinal detachment
Most Recent Events
- 01 Feb 2023 Discontinued - Preclinical for Age-related macular degeneration in Japan (Topical)
- 19 Feb 2021 Discontinued - Phase-I/II for Retinal detachment (Treatment-experienced) in Japan (Topical) (Mallinckrodt Pharmaceuticals pipeline, February 2021)
- 28 May 2018 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in Japan (Ophthalmic, Drops)